Almost anything is possible in the OTC, that I won't argue with.
This may still have some potential; however, with $110k in annual revenue for Modevity/ARALOC, as per Dun & Bradstreet, the million dollar revenue narrative holds no weight without a SEC filing:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.